Teva, Gilead settle US patent dispute over generic version of Viread
Teva and Gilead Sciences agreed to settle a US patent dispute over the HIV and chronic hepatitis B therapy Viread (tenofovir), avoiding a trial that was scheduled to start Wednesday, Gilead reported. Under the deal, Teva will be allowed to launch a generic version of Viread on December 15, 2017.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.